Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin

BACKGROUND: The residual risk that remains after statin treatment supports the addition of other LDL-C-lowering agents and has stimulated the search for secondary treatment targets. Epidemiological studies propose HDL-C as a possible candidate. Cholesteryl ester transfer protein (CETP) transfers cho...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Heart J
Main Authors: Kühnast, Susan, van der Tuin, Sam J.L., van der Hoorn, José W.A., van Klinken, Jan B., Simic, Branko, Pieterman, Elsbet, Havekes, Louis M., Landmesser, Ulf, Lüscher, Thomas F., Willems van Dijk, Ko, Rensen, Patrick C.N., Jukema, J. Wouter, Princen, Hans M.G.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
Basic Science
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4286319/
https://ncbi.nlm.nih.gov/pubmed/25142968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehu319
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados